Menu Search
Equities

EyePoint Pharmaceuticals Inc

PV3B:MUN

EyePoint Pharmaceuticals Inc

Actions
  • Price (EUR)8.52
  • Today's Change0.236 / 2.85%
  • Shares traded0.00
  • 1 Year change+57.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 16:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

  • Revenue in USD (TTM)45.71m
  • Net income in USD-103.57m
  • Incorporated2008
  • Employees121.00
  • Location
    EyePoint Pharmaceuticals Inc480 Pleasant St Ste B300WATERTOWN 02472-2468United StatesUSA
  • Phone+1 (617) 926-5000
  • Fax+1 (617) 926-5050
  • Websitehttps://eyepointpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.